Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250767 | 1.00 | KDM4E (0.51) | KDM4ENPSR1CYP3A4THRBTSHR | |
| SCHEMBL3250768 | 1.00 | KDM4E (0.51) | KDM4ENPSR1CYP3A4THRBTSHR | |
| SCHEMBL9652240 | 1.00 | KDM4E (0.51) | KDM4ENPSR1CYP3A4THRBTSHR | |
| SCHEMBL9652237 | 1.00 | KDM4E (0.51) | KDM4ENPSR1CYP3A4THRBTSHR | |
| Hydrochloric Acid SCHEMBL29358906 | 0.98 | KDM4E (0.50) | KDM4ENPSR1CYP3A4THRBTSHR | |
| Hydrochloric Acid SCHEMBL1793245 | 0.98 | KDM4E (0.50) | KDM4ENPSR1CYP3A4THRBTSHR | |
| Hydrochloric Acid SCHEMBL1793249 | 0.98 | KDM4E (0.50) | KDM4ENPSR1CYP3A4THRBTSHR | |
| Hydrochloric Acid SCHEMBL1793247 | 0.98 | KDM4E (0.50) | KDM4ENPSR1CYP3A4THRBTSHR | |
| SCHEMBL11059909 | 0.82 | CYP3A4 (0.43) | KDM4ENPSR1CYP3A4THRBTSHR | |
| SCHEMBL9652192 | 0.81 | MAPT (0.45) | KDM4ENPSR1CYP3A4THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285797-A1 | USE OF INHIBITORS OF CYP2A6 FOR REGULATING NICOTINE METABOLISM | NICOGEN INC. (CA) | 2009-11-19 | — | — | US | claimed |
| US-20050032844-A1 | Screening for substances that regulate the metabolic conversion of nicotine to cotinine such as enzyme inhibiters of CYP2A6, a member of the cytochrome P450 (CYP) system and the major nicotine metabolizing enzyme in human livers; also assaying for selective inhibitors of the gene expression of CYP2A6 | NICOGEN, INC. (CA) | 2005-02-10 | — | — | US | claimed |
| EP-0954304-A2 | METHODS FOR REGULATING NICOTINE METABOLISM | Nicogen Inc. (CA) | 1999-11-10 | — | — | EP | claimed |
| WO-1998003171-A2 | USE OF INHIBITORS OF CYP2A6 FOR REGULATING NICOTINE METABOLISM | NICOGEN INC. (CA) | 1998-01-29 | — | — | WO | claimed |
| US-4992455-A | Cardiovascular disorders | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | claimed |
| JP-9208493-A | — | — | None | — | — | JP | disclosed |
| JP-4095092-A | — | — | None | — | — | JP | disclosed |
| JP-7206859-A | — | — | None | — | — | JP | disclosed |
| JP-1279882-A | — | — | None | — | — | JP | disclosed |
| EP-1033979-B2 | COMBINATION OF CYP2A6 ENZYME INHIBITORS AND NICOTINE AND THEIR THERAPEUTIC USE | NICOGEN INC (CA) | 2010-02-24 | — | — | EP | disclosed |
| US-20090285797-A1 | USE OF INHIBITORS OF CYP2A6 FOR REGULATING NICOTINE METABOLISM | NICOGEN INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090285797-A1 | USE OF INHIBITORS OF CYP2A6 FOR REGULATING NICOTINE METABOLISM | NICOGEN INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| EP-0292305-B1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES AND ACID ADDITION SALTS THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-5106860-A | Treating inflammation, circulatory disease, gastrointestinal ulceration, allergies | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-04-21 | — | — | US | disclosed |
| JP-H0495092-A | PRODUCTION OF (+)-CIS-3,5-DIMETHYL-2-(3-PYRIDYL)THIAZOLIDIN-4-ONE | SUMITOMO CHEM CO LTD | 1992-03-27 | — | — | JP | disclosed |
| US-5021435-A | Administering to a patient suffering from an ulcer caused by stress or gastric acid | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-06-04 | — | — | US | disclosed |
| US-4992455-A | Cardiovascular disorders | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | disclosed |
| JP-H01279882-A | NOVEL THIAZOLIDINE-4-ONE DERIVATIVE AND ACID ADDITION SALT THEREOF | SUMITOMO PHARMACEUT CO LTD | 1989-11-10 | — | — | JP | disclosed |
| EP-0325496-A1 | 2-Pyridyl thiazolidin-4-one derivatives as anti-ulcer agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-07-26 | — | — | EP | disclosed |
| EP-0292305-A1 | Novel thiazolidin-4-one derivatives and acid addition salts thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285797-A1 | USE OF INHIBITORS OF CYP2A6 FOR REGULATING NICOTINE METABOLISM | CYP2A6, CYP2B6, CYP2D6 | KDM4E 2189/4885NPSR1 1206/4885CYP3A4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.